RESUMO
Venous thromboembolism (VTE) is frequently encountered across various specialties. The management of VTE has become more nuanced, requiring consideration of several factors when deciding on the choice and duration of anticoagulation. This evidence-based review article summarises the current practice and evidence behind anticoagulation in VTE, incorporating national and international guidelines. Factors influencing decision-making around the choice and duration of anticoagulation, along with special circumstances such as cancer and antiphospholipid syndrome, are discussed. The clinical utility of thrombophilia screening is also addressed.
Assuntos
Médicos , Tromboembolia Venosa , Humanos , Tromboembolia Venosa/diagnóstico , Tromboembolia Venosa/tratamento farmacológico , Tromboembolia Venosa/prevenção & controle , Anticoagulantes/uso terapêutico , Serviços de Saúde , Fatores de RiscoRESUMO
Tyrosine kinase inhibitors (TKI) are an increasingly used class of anti-cancer agent. Sunitinib (sutent(®), Pfizer™, New York) is standard first-line therapy for patients with metastatic renal cancer. It is associated with a number of toxicities, including thyroid dysfunction. We present a case of sunitinib-induced severe hypothyroidism resulting in cardiac compromise. The case highlights the importance of interval thyroid function monitoring for patients on drugs, such as sunitinib and other TKIs.